The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 16, 2021

Filed:

Apr. 10, 2019
Applicant:

Arrowhead Pharmaceuticals, Inc., Pasadena, CA (US);

Inventors:

Zhen Li, Monona, WI (US);

Tao Pei, Monona, WI (US);

Agnieszka Glebocka, Madison, WI (US);

Michael Lawler, Madison, WI (US);

Fred Fleitz, Germantown, WI (US);

Erich Altenhofer, Madison, WI (US);

Pankaj Kumar, Madison, WI (US);

Assignee:

Arrowhead Pharmaceuticals, Inc., Pasadena, CA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/113 (2010.01); A61K 31/711 (2006.01); A61K 47/54 (2017.01); C07H 21/02 (2006.01); A61K 31/7008 (2006.01); A61K 31/7105 (2006.01); C07H 5/06 (2006.01); C07H 21/04 (2006.01); A61K 31/713 (2006.01);
U.S. Cl.
CPC ...
C12N 15/113 (2013.01); A61K 31/7008 (2013.01); A61K 31/711 (2013.01); A61K 31/713 (2013.01); A61K 31/7105 (2013.01); A61K 47/549 (2017.08); A61K 47/555 (2017.08); C07H 5/06 (2013.01); C07H 21/02 (2013.01); C07H 21/04 (2013.01); C12N 2310/14 (2013.01); C12N 2310/31 (2013.01); C12N 2310/315 (2013.01); C12N 2310/317 (2013.01); C12N 2310/321 (2013.01); C12N 2310/322 (2013.01); C12N 2310/332 (2013.01); C12N 2310/351 (2013.01); C12N 2310/3515 (2013.01); C12N 2310/3517 (2013.01); C12N 2320/32 (2013.01);
Abstract

Described are novel targeting ligands that may be linked to compounds, such therapeutic compounds that are useful in directing the compounds to the in vivo target. The targeting ligands disclosed herein can serve to target expression-inhibiting oligomeric compounds, such as RNAi agents, to liver cells to modulate gene expression. The targeting ligands disclosed herein, when conjugated to a therapeutic compound, may be used in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Compositions including the targeting ligands disclosed herein when linked to expression-inhibiting oligomeric compounds are capable of mediating expression of target nucleic acid sequences in liver cells, such as hepatocytes, which may be useful in the treatment of diseases or conditions that respond to inhibition of gene expression or activity in a cell, tissue, or organism.


Find Patent Forward Citations

Loading…